medigraphic.com

2006, Number 4

<< Back Next >>

Rev Fac Med UNAM 2006; 49 (4)

Helicobacter pylori and associate infections

Cervantes GE

Language: Spanish
References: 66
Page: 163-168
PDF size: 86.52 Kb.


Text Extraction

No abstract


REFERENCES

  1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-1275.

  2. Parsonnet J. Helicobacter pylori: The size of the problem. Gut 1998; 43: S6-S9.

  3. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89: S116-S128.

  4. III° Simposio Internacional de Patología Gastroduodenal “Helicobacter pylori” Primer Consenso Argentino para su Diagnóstico y Tratamiento. Abril 2000.

  5. Pakodi F, Abdel-Salam OM, Debreceni A, Mozsik G. Helicobacter pylori, one bacterium and a broad spectrum of human disease’An overview. J Physiol Paris 2000; 94: 139-152.

  6. Cave DR. Epidemiology and transmission of Helicobacter pylori infection. How is Helicobacter pylori transmitted? Gastroenterology 1997; 113: S9-S13.

  7. Torres J, Leal-Herrera Y, Perez-Perez GI, Gomez A, Camorlinga Ponce M. A community-based Seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis 1998: 1089-1094.

  8. Ewerhart JE, Kruszon-Moran D, Pérez-Perez GI. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000; 181: 1359-1363.

  9. Torres J. Aspectos epidemiológicos y clínicos de la infección por Helicobacter pylori en niños. Rev Gastroenterol Mex 2000; 65: 13-1.

  10. Bardhan PK. Epidemiological features of Helicobacter pylori infection in developing countries. Clin Infect Dis 1997; 25: 973-978.

  11. Forman D, Goodman KJ. The epidemiology of stomach cancer: correlating the past with the present socioeconomic influences early life can influence mortality in adult life. BJM 2003; 320: 1682-1683.

  12. Guarner J, Mohar A, Parsonnet J. The association of Helicobacter pylori with gastric cancer and pre-neoplasic gastric lesions in Chiapas Mexico. Cancer 1993; 71: 297-301.

  13. Dobois A, Berg DE, Incecik ET, Fiala N, Heman-Ackah LM. Transient and persistent infection of nonhuman primates with Helicobacter pylori: Implications for human disease. Infect Immun 1996; 64: 2885-2886.

  14. Mazari-Hiriart M, Lopez-Vidal Y, Calva JJ. Helicobacter pylori water systems for human use in Mexico City. Water Sci Technol 2001; 43: 93-98.

  15. Mazari-Hirart M, López-Vidal Y, Castillo-Rojas G, Ponce de León S. Helicobacter pylori and other enteric bacteria in freshwater environments in Mexico City. Arch Med Res 2001; 32: 458-467.

  16. Blaser JM. Helicobacter pylori. Prince and pract inf dis. Update 1991; 9: 3-9.

  17. Goodwin C, Armstrong J, Peters M. Microbiology of Campylobacter pylori. In: Blaser M, Ed Campylobacter pylori in gastritis and peptic ulcer disease. New York, Medical Publishers; 1989: 25-49.

  18. Koneman EW, Allen SD, Schreckenberger PC, Winn WC. Color Atlas and Textbook of Diagnostic Microbiology, Lippincott Willian and Wilkins, Fifth Edition, 1997: 335-39.

  19. Rivas TF, Hernández F. Helicobacter pylori: factores de virulencia, patología y diagnóstico. Rev Biomed 2000; 11: 187-205.

  20. McGee DJ, Mobley HL. Mechanisms of Helicobacter pylori infection: Bacterial factors. Curr Top Microbiol Immunol 1999; 241: 155-180.

  21. Dunn B, Campbell G, Perez-Perez G. Purification and characterization of urease from Helicobacter pylori. J Biol Chem 1990; 265: 9464-9468.

  22. Fox JG, Correa P, Taylor NS, Thompson N, Fontham E. High prevalence and persistence of cytotoxin-positive Helicobacter pylori strains in a population with high prevalence of atrophic gastritis. Am J Gastroenterol 1992; 87: 1554-1560.

  23. Cover TL, Puryear W, Perez-Peres GI, Blaser MJ. Effect os urease on HeLa cell vacuolating induced by Helicobacter pylori cytotoxin. Infect Immun 1991; 59: 1264-1270.

  24. Eaton KA, Morgan DR, Krakowka S. Motility as a factor in the colonization of gnotobiotic piglets by Helicobacter pylori. J Med Microbiol 1992; 37: 123-127.

  25. Geis G, Surebaum S, Forsthoff B, Leying H. Ultrastructure and biochemical studies of the flagellar sheath of Helicobacter pylori. J Med Microbiol 1993; 38: 371-377.

  26. Josenhans C, Labigne A, Suyrebaum S. Comparative ultrastructural and functional studies of Helicobacter pylori and Helicobacter mustelae flagellin mutants: Both flagellin subunits, FlaA and FlaB ase necessary for ful motility in Helicobacter species. J Bacteriol 1995; 177: 3010-3020.

  27. Wadstrom T, Hirmo S, Boren T. Biochemical aspects of Helicobacter pylori colonization of human gastric mucosa. Aliment Pharmacol Ther 1996; 10: 17-27.

  28. Mahdavi J, Sondén B, Hurtig M, Olfat FO. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002; 297: 573-578.

  29. Moran AP. Helicobacter pylori lipopolysaccharide-mediated gastric and extragastric pathology. J Physiol Pharmacol 1999; 50: 787-805.

  30. Bliss CM, Golenblock DT, Kates S, Linevsky JK. Helicobacter pylori lipopolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial neutrophil-activating peptide 78, and monocyte chemotactic protein 1 by human monocytes. Infect Immun 1998; 66: 5357-5363.

  31. Abdulhamid M, Alkout M, Blackwell CC. Increases inflammatory responses of persons of blood group O to Helicobacter pylori. J Infect Dis 2000; 181: 1364-1369.

  32. Aspinall GO, Monteiro MA. Lipopolysaccharide of Helicobacter pylori strains P466 and MO19: structure of the O antigen and core oligosaccharide strains. Biochemestry 1996; 35: 2498-2504.

  33. Appelmelk BJ, Martino MC, Veenhoff F. Phase variation in H type 1 and Lewis a epitopes of Helicobacter pylori lipopolisaccharide. Infec Immun 2000; 68: 5928-5932.

  34. Covacci A, Rappouli R. Helicobacter pylori: Molecular evolution of a bacterial quasispecies. Curr Opin Microbiol 1998; 1: 96-102.

  35. Ge Z, Taylor D. Contributions of genome sequencing to understanding the biology m of Helicobacter pylori. Anu Reb Microbiol 1999; 53:355-387.

  36. Hacker J, Blum-Oehler G, Muhidorfer I. Pathogenicity island of virulent bacterial structure, function and impact on microbial evolution. Mol Microbiol 1997; 23: 1089-1097.

  37. Covacci A, Censini S, Bugnoli M. Molecular characterization of the 128 kDa immunodominant antigen of Helicobacter pylori: Associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993; 90: 5791-5795.

  38. Evans D, Quiroz D, Mendes E. Helicobacter pylori CagA Status and s and m alleles of VacA in isolates from individuals with a variety of H. pylori: Associated Gastric Disease. J Clin Microbiol 1998; 36: 3435-3437.

  39. Xiang Z, Censini S, Bayeli PF, Teleford JL. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two mayor types and that CagA is not necessary for expression of the vacuolating toxin. Infect Immun 1995; 63: 94-98.

  40. Segal ED, Falkow S, Tompkins LS. Helicobacter pylori attachment to gastric cells induces cytoskeletal rearrangement and tyrosine phosphorilation of host cell protein. Proc Natl Acad Sci 1996; 93: 1259-1264.

  41. Stein M, Rappuoli R, Covacci A. Tyrosine phosphorilation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci 2000; 97: 1263-1268.

  42. Dundon WG, De Bernard M, Montecucco C. Virulence factors of Helicobacter pylori. Int J Med Microbiol 2001; 290: 647-658.

  43. Higashi H, Tsutsumi R, Fujita A, Yamasaki S. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine fosforilation sites. Proc Natl Acad Sci 2002; 99: 14428-14433.

  44. Blase M, Perez-Perez GI, Kleanthous H, Cover T. Infection with Helicobacter pylori strains possessing cagA is associates with an increased risk of developing adenocarcinoma in the stomach. Cancer Res 1995; 55: 2111-2115.

  45. Maeda S, Ogura K, Yoshida H, Funai F. Major virulence factors, VacA and CagA are commonly positive in Helicobacter pylori isolates in Japan. Gut 1998; 42: 338-343.

  46. Nomura A, Stemmarmann G, Chyan P, Perez-Perez GI. Helicobacter pylori infection and risk for duodenal and gastric ulceration. An Inter Med 1994; 120: 977-981.

  47. Bernard A, Papini E, Filoppis V, Gottardi E. Low pH activates the vauolating toxin of Helicobacter pylori, which becomes acid and pepsin resistant. J Biol Chem 1995; 270: 23937-23940.

  48. Rudi J, Kolb C, Maiwald M, Kick D. Diversity of Helicobacter pylori vac A and cagA genes and relationship to vacA and protein expression cytotoxin production and associated diseases. J Clin Microbiol 1998; 36: 944-948.

  49. Weel JF, van der Huist Ewm, Gerrits Y. The interrelationship between Cytotoxin-A associated Gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis 1998; 173: 1171-1175.

  50. Dumm BE, Cohen H. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 72041.

  51. Savalino V, Vinerie S, Celle G. The 13C-urea breath test in the diagnosis of Helicobacter pylori infection. Gut 1999; 45: 18-22.

  52. Lahner E, Vaira D, Figura N, Pilozzi E, Pasquali A. Role of non invasive test (C13 Urea Test Breat and stool antigen test) as aditional tools in diagnosis of Helicobacter pylori in patients with atrophic body gastritis. Helicobacter 2004; 9: 436-438.

  53. Perez-Perez CI, Cutler AF, Blaser MJ. Value of serology as a non invasive method to evaluate the efficacy of treatment in Helicobacter pylori infection. Clin Microbiol 2002; 28: 103-110.

  54. Loy Ct, Irwing LM, Katerekeis PH. Do commercial serological kits for Helicobacter pylori infection differ in accuracy. A meta-analysis. Am J Gastroenterol 1996; 91: 1138-1144.

  55. Perez TE, Montes M, Alcorta M. Non endoscopie method to obtain Helicobacter pylori for culture. Lancet 1995; 345: 622-623.

  56. Leodolter A, Agha-Amiri K, Peitz U, Gerards C. Validity of a Helicobacter pylori stool antigen assay for the assessment of Helicobacter pylori status following eradication therapy. Eur J Gastroenterol Hepatol 2001; 13: 673-676.

  57. Vaira D, Holton J, Menegatti. New immunological assay for the diagnosis of Helicobacter pylori infection. Gut 1999; 45: 23-27.

  58. Monteiro L, Gras N, Vidal R. Detection of Helicobacter pylori DNA in human feces by PCR, DNA stability and removal inhibitors. J Microbiol Meth 2001; 45: 89-94.

  59. Monteiro L, Gras N, Mégraud F. Magnetic immuno-PCR assay with inhibitor removal for direct detection of Helicobacter pylori in human feces. J Clin Microbiol 2001; 39: 3778-37780.

  60. Lara LF, Cisneros Gm, Gurney M. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch J Med 2003; 163: 2079-2084.

  61. Zullo A, Vaira D, Vakil N. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-726.

  62. Sanjuro JL, Pérez J, Hidalgo H, Geyne A. Eficacia y seguridad entre diferentes dosis de nitazoxanida + subcitrato de bismuto + lanzoprazol para la erradicación de Helicobacter pylori. Revista Médica del Hospital General de México 1999; 14: 172-175.

  63. Bazzoli F. Key points from the revised Maastrich consensus Report: the impact general practice. Eur J Gastroenterol Hepatol 2001; 13: S3-S7.

  64. Miwa H, Ohkura R, Murai T. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection comparison with omeprazole and lansoprazole.

  65. Gasbarrini A, Franceschi F, Gasbarrini G. Extraintestinal pathology associated with Helicobacter infection. Eur J Gastroenterol Hepatol 1997; 23: 231-233.

  66. Leontiadis GI, Sharman VK, Howden CW. Non-gastrointestinal tract associations of Helicobacter pylori infection. Arch Intern Med 1999; 159: 925-940.




2020     |     www.medigraphic.com